8 October 2015PharmaNatalia Wegner-Cribbs and Daniel Wise
A clearer picture for SPCs?
On October 6, the Court of Justice of the European Union (CJEU) delivered its judgment in case C-471/14. It clarified that the term of a supplementary protection certificate (SPC) is determined with reference to the date on which a marketing authorisation is notified to that applicant. This means that in many cases SPC owners that do not already benefit from the maximum five-year term will get some additional term for their products, although it remains to be seen how and to what extent the judgment will be implemented from a practical point of view by the various national patent offices. The judgment may also have implications for aspects of SPC law other than the SPC term, on which the CJEU did not provide any guidance.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.
11 August 2026 A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
10 August 2026 Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.